Search Results - "Vollmer, T.L."

Aggressive Natalizumab Treatment For Jc Virus-Negative Relapsing-Remitting Multiple Sclerosis? Cost-Effectiveness Of First-Line Versus Second-Line Natalizumab Treatment by McQueen, R.B, Nair, K.V, Vollmer, T.L, Campbell, J.D

Get full text

CD4+ CD25+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis by Jee, Y, Piao, W.H, Liu, R, Bai, X.F, Rhodes, S, Rodebaugh, R, Campagnolo, D.I, Shi, F.D, Vollmer, T.L

“…Abstract CD4+ CD25+ regulatory T cells (Tregs) are potent immunosuppressors that are pivotal in the maintenance of self-tolerance. The involvement of Tregs in…”
Get full text

A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin by Zhao, C.B., Coons, S.W., Cui, M., Shi, F.D., Vollmer, T.L., Ma, C.Y., Kuniyoshi, S.M., Shi, J.

“…Experimental autoimmune encephalomyelitis (EAE) is a primary animal model of multiple sclerosis (MS). MS predominantly presents with evidence of lesions in the…”
Get full text

PND19 - Aggressive Natalizumab Treatment For Jc Virus-Negative Relapsing-Remitting Multiple Sclerosis? Cost-Effectiveness Of First-Line Versus Second-Line Natalizumab Treatment by McQueen, R.B., Nair, K.V., Vollmer, T.L., Campbell, J.D.

Get full text

IL-21 Modulates CD4⁺ CD25⁺ Regulatory T-Cell Homeostasis in Experimental Autoimmune Encephalomyelitis by Piao, W.-H, Jee, Y.H, Liu, R.L, Coons, S.W, Kala, M, Collins, M, Young, D.A, Campagnolo, D.I, Vollmer, T.L, Bai, X.-F, La Cava, A, Shi, F.-D

“…The homeostasis of CD4 ⁺ CD25 ⁺ regulatory T cells (Tregs) depends on the cytokine interleukin (IL)-2. As IL-21 shares sequence homology with IL-2 and the…”
Get full text

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS by SHEREMATA, W. A, VOLLMER, T. L, STONE, L. A, WILLMER-HULME, A. J, KOLLER, M

“…A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was…”
Get full text